Distinct immunologic patterns of response and resistance to anti-PD-1/PD-L1-based immunotherapy in patients with soft tissue sarcoma - PubMed
4 hours ago
- #soft tissue sarcoma
- #biomarkers
- #immune checkpoint inhibitors
- Chemotherapy is the standard treatment for metastatic soft tissue sarcoma (STS), but its benefits are limited.
- Immune checkpoint inhibitors (ICIs) like anti-PD-1/PD-L1 have variable efficacy in STS, mainly effective in undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated liposarcoma (LPS).
- The study analyzed mutation profiles and longitudinal blood samples from 13 STS patients treated with anti-PD-1/PD-L1 therapy to identify immune correlates of response.
- Elevated circulating lymphoid cells were associated with response, while innate immune populations (neutrophils, monocytes) correlated with non-response.
- Single-cell RNA sequencing of PBMCs from a patient with prolonged stable disease showed dynamic shifts in monocyte and CD8 T cell phenotypes linked to tumor regression and progression.
- Peripheral immune profiles could serve as biomarkers for predicting and monitoring ICI efficacy in STS, improving patient selection and treatment strategies.